Michael T Hallett
Overview
Explore the profile of Michael T Hallett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
762
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Case N, Westman J, Hallett M, Plumb J, Farheen A, Maxson M, et al.
mBio
. 2023 Dec;
14(6):e0274523.
PMID: 38038475
is a leading human fungal pathogen that often causes life-threatening infections in immunocompromised individuals. The ability of to transition between yeast and filamentous forms is key to its virulence, and...
2.
Dumeaux V, Massahi S, Bettauer V, Mottola A, Dukovny A, Khurdia S, et al.
Elife
. 2023 Oct;
12.
PMID: 37888959
an opportunistic human pathogen, poses a significant threat to human health and is associated with significant socio-economic burden. Current antifungal treatments fail, at least in part, because can initiate a...
3.
Bettauer V, Costa A, Omran R, Massahi S, Kirbizakis E, Simpson S, et al.
Microbiol Spectr
. 2022 Aug;
10(5):e0147222.
PMID: 35972285
We present deep learning-based approaches for exploring the complex array of morphologies exhibited by the opportunistic human pathogen Candida albicans. Our system, entitled Candescence, automatically detects C. albicans cells from...
4.
Busby M, Hallett M, Plante I
Int J Mol Sci
. 2018 Mar;
19(3).
PMID: 29495625
Gap junction transmembrane channels allow the transfer of small molecules between the cytoplasm of adjacent cells. They are formed by proteins named connexins (Cxs) that have long been considered as...
5.
Saleh S, Bertos N, Gruosso T, Gigoux M, Souleimanova M, Zhao H, et al.
Cancer Res
. 2017 Jun;
77(17):4673-4683.
PMID: 28652250
Triple-negative breast cancer (TNBC) is a molecularly heterogeneous cancer that is difficult to treat. Despite the role it may play in tumor progression and response to therapy, microenvironmental (stromal) heterogeneity...
6.
Paquet E, Cui J, Davidson D, Pietrosemoli N, Hassan H, Tsofack S, et al.
J Pathol Clin Res
. 2016 Aug;
1(3):160-72.
PMID: 27499901
Currently, there is no marker in use in the clinical management of colon cancer to predict which patients will respond efficiently to 5-fluorouracil (5-FU), a common component of all cytotoxic...
7.
Jones L, Broz M, Ranger J, Ozcelik J, Ahn R, Zuo D, et al.
Cancer Res
. 2016 Jan;
76(6):1416-28.
PMID: 26719528
Immunosurveillance constitutes the first step of cancer immunoediting in which developing malignant lesions are eliminated by antitumorigenic immune cells. However, the mechanisms by which neoplastic cells induce an immunosuppressive state...
8.
Ali-Khan S, Black L, Palmour N, Hallett M, Avard D
Int J Technol Assess Health Care
. 2015 May;
31(1-2):36-50.
PMID: 25991501
Objectives: There have been multiple calls for explicit integration of ethical, legal, and social issues (ELSI) in health technology assessment (HTA) and addressing ELSI has been highlighted as key in...
9.
Paquet E, Hallett M
J Natl Cancer Inst
. 2014 Dec;
107(1):357.
PMID: 25479802
Background: Massively parallel gene expression profiling has provided a more objective, molecular-level characterization of breast cancer subtypes. Several bioinformatics tools are available to infer patient subtype from a gene expression...
10.
Knight J, Lesurf R, Zhao H, Pinnaduwage D, Davis R, Saleh S, et al.
Proc Natl Acad Sci U S A
. 2013 Mar;
110(14):E1301-10.
PMID: 23509284
Triple-negative breast cancer (TNBC) accounts for ∼20% of cases and contributes to basal and claudin-low molecular subclasses of the disease. TNBCs have poor prognosis, display frequent mutations in tumor suppressor...